- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about European Medicines Agency
Recent news which mentions European Medicines Agency
European Regulator Expands Ozempic Probe To Include Other Weight Loss Drugs Over Suicide Risks
July 11, 2023
From Benzinga
European Drug Authority Raises Thyroid Cancer Safety Signal For Novo Nordisk Drugs, Including Hyped Semaglutide
June 22, 2023
From Benzinga
Europe Approves Xofluza, Roche's Revolutionary Influenza Antiviral with New Mechanism
January 12, 2023
From Benzinga
Europe Approves AstraZeneca's Two Combo Therapies For Prostate, Bile Duct Cancer Settings
December 21, 2022
From Benzinga
Regeneron-Sanofi's Dupixent Wins European Approval For Prurigo Nodularis
December 15, 2022
From Benzinga
Europe Approves Mirum Pharma's Drug For Rare Genetic Liver Disease
December 13, 2022
Tickers
MIRM
From Benzinga
Europe Approves Sanofi's Enjaymo For Rare Form Of Anemia
November 17, 2022
Tickers
SNY
From Benzinga
European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
November 14, 2022
From Benzinga
Europe Approves Agios Pharma's Mitapivat For Adult Pyruvate Kinase Deficiency Patients
November 11, 2022
Tickers
AGIO
From Benzinga
Europe Approves Sanofi, GSK's Beta Variant Adapted COVID Shot As Booster
November 10, 2022
From Benzinga
Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants
November 04, 2022
From Benzinga
After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns
October 31, 2022
From Benzinga
European Regulatory Authority Backs Approval For Moderna's New Omicron Targeted COVID-19 Booster
October 19, 2022
Tickers
MRNA
From Benzinga
Europe Approves First CAR T-Cell Therapy For B-Cell Lymphoma In 30 Years to Improve Upon Standard of Care
October 18, 2022
Tickers
GILD
From Benzinga
European Heath Agency's Committee Backs Approving BeiGene's Brukinsa In Leukemia Setting
October 14, 2022
Tickers
BGNE
From Benzinga
Europe's Health Agency Accepts Moderna's Filing For Its Updated Omicron-Targeted COVID-19 Vaccine
September 28, 2022
Tickers
MRNA
From Benzinga
AstraZeneca's Asthma Treatment Scores European Approval
September 21, 2022
From Benzinga
Europe Approves First Bispecific Antibody From Roche For Two Eye Disorders
September 19, 2022
From Benzinga
European Authority Backs AbbVie's Crohn's Disease Candidate
September 19, 2022
Tickers
ABBV
From Benzinga
Bristol Myers' Opdivo Combo Treatment Scores European Approval For Skin Cancer Setting
September 19, 2022
Tickers
BMY
From Benzinga
AstraZeneca's COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing
September 16, 2022
From Benzinga
From Benzinga
From Benzinga
Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients
August 25, 2022
From Benzinga
Gilead's Lenacapavir Scores European Approval For Pretreated HIV Patients After Manufacturing Delays
August 22, 2022
From Benzinga
Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder
August 22, 2022
From Benzinga
Read Why Aeglea BioTherapeutics Shares Are Skyrocketing Today?
August 19, 2022
Tickers
AGLE
From Benzinga
Bavarian Nordic's Monkeypox Vaccine Scores EU Approval As WHO Declares Global Health Emergency
July 25, 2022
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.